A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer

Published:2011-11-09 Issue:13 Volume:118 Page:3283-3293
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Secord Angeles Alvarez,Berchuck Andrew,Higgins Robert V.,Nycum Lawrence R.,Kohler Matthew F.,Puls Larry E.,Holloway Robert W.,Lewandowski George S.,Valea Fidel A.,Havrilesky Laura J.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26610/fullpdf

Reference47 articles.

1. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study;González-Martín;Ann Oncol,2005

2. Gemcitabine plus carboplatin compared to carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J Clin Oncol,2006

3. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial;Parmar;Lancet,2003

4. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy;Bookman;Oncologist,1999

5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model;Horowitz;Gynecol Oncol,2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Data presentation of results from randomized cancer clinical trials. The case for trials in advanced cervical cancer. A critical appraisal.;F1000Research;2023-03-13

2. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line;British Journal of Cancer;2023-02-09

3. Modeling of the natural groundwater recharge under climate change: Sisseb El Alem Nadhour Saouaf basin (Central Tunisia) case study;Environmental Earth Sciences;2020-06

4. Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline;Current Oncology;2017-12-01

5. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer—A Phase 2 Cohort Study;International Journal of Gynecologic Cancer;2016-05